IGF1R and neoplasm: In particular, linsitinib induces tumor cell death through IGF1R pathway inhibition and, at the same time, decreases the expression of CAR T-cell exhaustion markers and increases their central memory profiles without interfering with their cytotoxic activity in vitro.